Results 21 to 30 of about 344,680 (247)

Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma [PDF]

, 2012
Copyright @ 2013 Macmillan Publishers Limited. This is the author's accepted manuscript. The final published article is available from the link below.Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM).
A Barbarulo, A Chaidos, A Karadimitris, A Rahemtulla, AJ Bardwell, C Bubici, C-H Yoon, CG Pham, CR Geest, D Chauhan, D O Haskard, E Spanoudakis, EF Wagner, F Bost, F Zazzeroni, F Zhan, F Zhan, G Franzoso, H Ke, H Ke, J Cui, J Cui, J Ford, J Liu, K Kim, K Naresh, K Pruitt, K Sabapathy, KC Anderson, KN Naresh, L Aravind, L Hui, LC Platanias, M Anbalagan, M Blonska, M Gururajan, M Hallek, M Raman, M Wiznerowicz, MA Bogoyevitch, MA Bogoyevitch, MS Raab, N Chen, NJ Kennedy, NN Gangopadhyay, RT Nitta, S Goenka, S Goenka, S Papa, S Papa, SH Cho, SH Cho, SU Ahmed, SV Rajkumar, T Hideshima, T Hideshima, T Hideshima, T Kajiguchi, T Yanagawa, TE Witzig, V Brune, V Iansante, V Schreiber, YM Yang   +63 more
core   +2 more sources

Multiple Myeloma [PDF]

Hematology, 2002
AbstractThis update provides new insights into the biology, diagnosis, prognosis, and treatment of multiple myeloma (MM) and its complications.In Section I, Drs. John Shaughnessy, Jr., and Bart Barlogie first correlate global gene microarray expression profiling of patient MM samples with normal plasma cells to provide the basis for a developmental ...
Kenneth C, Anderson, John D, Shaughnessy, Bart, Barlogie, Jean-Luc, Harousseau, G David, Roodman   +4 more
openaire   +2 more sources

Extracellular Vesicles in Hematological Malignancies: From Biomarkers to Therapeutic Tools

Diagnostics, 2020
Small extracellular vesicles (EVs) are a heterogenous group of lipid particles released by all cell types in physiological and pathological states.
Jihane Khalife, James F. Sanchez, Flavia Pichiorri   +2 more
doaj   +1 more source

Myeloma multiplex with pulmonary dissemination [PDF]

, 2014
Introduction. Multiple myeloma is a hemathological malignancy characterized by the clonal proliferation of plasma cells in the bone the marrow. Extramedullary dissemination of multiple myeloma is uncommon.
Maksić Đoko, Mijušković Mirjana, Obrenčević Katarina, Petrović Marijana, Petrović Milica, Pilčević Dejan, Tadić-Pilčević Jelena, Terzić Brankica, Čukić Zoran, Škuletić Vesna   +9 more
core   +1 more source

Phagocytic plasma cells in a patient with multiple myeloma [PDF]

, 1995
Phagocytosis of blood cells by malignant plasma cells in multiple myeloma is an extremely rare condition. Here we present a 39-year-old woman with multiple myeloma.
Hagemeijer, A. (Anne), Leeuw, K. (K.) de, Löwenberg, B. (Bob), Vanhagen, P.M. (P.)   +3 more
core   +1 more source

ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma

npj Precision Oncology, 2023
Optimal first-line treatment that enables deeper and longer remission is crucially important for newly diagnosed multiple myeloma (NDMM). In this study, we developed the machine learning (ML) models predicting overall survival (OS) or response of the ...
Sung-Soo Park, Jong Cheol Lee, Ja Min Byun, Gyucheol Choi, Kwan Hyun Kim, Sungwon Lim, David Dingli, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hwan Shin, Chang-Ki Min, Jamin Koo   +11 more
doaj   +1 more source

Multiple Myeloma [PDF]

Current Problems in Cancer, 2009
Multiple myeloma is characterised by clonal proliferation of malignant plasma cells, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis. This knowledge has already expanded treatment options for patients with multiple myeloma.
Marc S, Raab, Klaus, Podar, Iris, Breitkreutz, Paul G, Richardson, Kenneth C, Anderson   +4 more
openaire   +4 more sources

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era

Experimental Hematology & Oncology, 2017
B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies.
Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu, Kenneth C. Anderson   +4 more
doaj   +1 more source

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

Blood Cancer Journal, 2022
Chimeric antigen receptor T cells (CAR T) are groundbreaking therapies but may cause significant toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias.
Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje   +10 more
doaj   +1 more source

The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment

Frontiers in Oncology, 2021
Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells (PCs) that develop at multiple sites within the bone marrow (BM). MM is treatable but rarely curable because of the frequent emergence of drug resistance and relapse.
Jihane Khalife, Jihane Khalife, James F. Sanchez, Flavia Pichiorri, Flavia Pichiorri   +4 more
doaj   +1 more source